Literature DB >> 21801777

Robust antigen-specific humoral immune responses to sublingually delivered adenoviral vectors encoding HIV-1 Env: association with mucoadhesion and efficient penetration of the sublingual barrier.

William Domm1, Lauren Brooks, Hung Li Chung, Changyong Feng, William J Bowers, Gene Watson, James L McGrath, Stephen Dewhurst.   

Abstract

The efficient induction of virus-specific mucosal antibodies is an important unmet objective in Human Immunodeficiency Virus Type-1 (HIV-1) vaccine research. One promising approach is sublingual (SL) immunization. We examined the effectiveness of SL delivery of two different viral vectors: (i) a recombinant adenovirus (rAd5), and (ii) a Herpes Simplex Virus Type-1 amplicon vector (HSV-1). Initial in vitro videomicroscopy experiments showed that rAd5 particles were trapped in saliva (i.e., that Ad5 was mucoadhesive) - unlike HSV-1 virions, which migrated freely in both saliva and water. In vivo imaging studies in mice revealed that only the rAd5 vector efficiently transduced the SL epithelium. Consistent with this, SL delivery of an rAd5 encoding HIV-1 envelope glycoprotein (Env) resulted in robust antigen-specific antibody responses in plasma and in vaginal washes, whereas SL delivery of a HSV-1 amplicon vector encoding HIV-1 Env failed to elicit Env-specific antibodies. In contrast, both vectors elicited equivalent humoral responses following intramuscular (IM) delivery. Finally, SL delivery of the rAd5:Env vector resulted in elevated levels of Env-specific serum IgA, and vaginal IgA and IgG, when compared to IM delivery of the same vector. These results findings shed light on vector properties (mucoadhesion, penetration of the sublingual barrier) which may be important for the induction of potent humoral immune responses following sublingual vector administration. Our data also show that SL delivery of an Env-encoding rAd5 vector can elicit a potent antigen-specific mucosal antibody response in the absence of adjuvant. Overall, these findings support the further exploration of the SL delivery route for HIV-1 vaccine delivery.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21801777      PMCID: PMC3167942          DOI: 10.1016/j.vaccine.2011.07.008

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  51 in total

1.  Image reconstruction reveals the complex molecular organization of adenovirus.

Authors:  P L Stewart; R M Burnett; M Cyrklaff; S D Fuller
Journal:  Cell       Date:  1991-10-04       Impact factor: 41.582

2.  Enhanced mucosal immunoglobulin A response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system.

Authors:  Franck Lemiale; Wing-pui Kong; Levent M Akyürek; Xu Ling; Yue Huang; Bimal K Chakrabarti; Michael Eckhaus; Gary J Nabel
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

3.  Protective effect of an oral infection with herpes simplex virus type 1 against subsequent genital infection with herpes simplex virus type 2.

Authors:  B Sturn; K E Schneweis
Journal:  Med Microbiol Immunol       Date:  1978-07-04       Impact factor: 3.402

4.  A simplified system for generating recombinant adenoviruses.

Authors:  T C He; S Zhou; L T da Costa; J Yu; K W Kinzler; B Vogelstein
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-03       Impact factor: 11.205

5.  A factorial survey study to assess the acceptability of HIV vaccine trial designs.

Authors:  M Hennessy; K MacQueen; D J McKirnan; S Buchbinder; F Judson; J M Douglas; B Bartholow; A Sheon
Journal:  Control Clin Trials       Date:  1996-06

6.  The composition f human saliva secreted in response to a gustatory stimulus and to pilocaprine.

Authors:  C Dawes
Journal:  J Physiol       Date:  1966-03       Impact factor: 5.182

7.  The role of epithelial cell differentiation in the expression of herpes simplex virus type 1 in normal human oral mucosa in culture.

Authors:  Y Yura; H Iga; K Terashima; H Yoshida; T Yanagawa; Y Hayashi; M Sato
Journal:  Arch Virol       Date:  1987       Impact factor: 2.574

8.  The effects of various secretagogues on the mucin content of pure submandibular salivas.

Authors:  P C Denny; P A Denny; M S Yim
Journal:  J Dent Res       Date:  1987-05       Impact factor: 6.116

9.  Human submandibular saliva aggregates HIV.

Authors:  D Malamud; C Davis; P Berthold; E Roth; H Friedman
Journal:  AIDS Res Hum Retroviruses       Date:  1993-07       Impact factor: 2.205

10.  Enhanced mucosal and systemic immune responses following intravaginal immunization with human papillomavirus 16 L1 virus-like particle vaccine in thermosensitive mucoadhesive delivery systems.

Authors:  Jeong-Sook Park; Yu-Kyoung Oh; Min-Jeong Kang; Chong-Kook Kim
Journal:  J Med Virol       Date:  2003-08       Impact factor: 2.327

View more
  9 in total

Review 1.  Microneedle-Mediated Vaccine Delivery to the Oral Mucosa.

Authors:  Rachel L Creighton; Kim A Woodrow
Journal:  Adv Healthc Mater       Date:  2018-12-10       Impact factor: 9.933

2.  Purification and functional characterization of mucosal IgA from vaccinated and SIV-infected rhesus macaques.

Authors:  Thomas Musich; Thorsten Demberg; Ian L Morgan; Jacob D Estes; Genoveffa Franchini; Marjorie Robert-Guroff
Journal:  Clin Immunol       Date:  2015-04-01       Impact factor: 3.969

Review 3.  Recent progress in mucosal vaccine development: potential and limitations.

Authors:  Nils Lycke
Journal:  Nat Rev Immunol       Date:  2012-07-25       Impact factor: 53.106

Review 4.  Towards the future exploration of mucosal mRNA vaccines against emerging viral diseases; lessons from existing next-generation mucosal vaccine strategies.

Authors:  Sodiq A Hameed; Stephane Paul; Giann Kerwin Y Dellosa; Dolores Jaraquemada; Muhammad Bashir Bello
Journal:  NPJ Vaccines       Date:  2022-06-28       Impact factor: 9.399

5.  Intra-cheek immunization as a novel vaccination route for therapeutic vaccines of head and neck squamous cell carcinomas using plasmo virus-like particles.

Authors:  Rodney Macedo; Juliette Rochefort; Maude Guillot-Delost; Kae Tanaka; Aline Le Moignic; Clara Noizat; Claude Baillou; Véronique Mateo; Antoine F Carpentier; Eric Tartour; Chloé Bertolus; Bertrand Bellier; Géraldine Lescaille; François M Lemoine
Journal:  Oncoimmunology       Date:  2016-07-06       Impact factor: 8.110

6.  Sublingual immunization with recombinant adenovirus encoding SARS-CoV spike protein induces systemic and mucosal immunity without redirection of the virus to the brain.

Authors:  Byoung-Shik Shim; Konrad Stadler; Huan Huu Nguyen; Cheol-Heui Yun; Dong Wook Kim; Jun Chang; Cecil Czerkinsky; Man Ki Song
Journal:  Virol J       Date:  2012-09-21       Impact factor: 4.099

7.  Mucosal immunization with recombinant adenovirus encoding soluble globular head of hemagglutinin protects mice against lethal influenza virus infection.

Authors:  Joo Young Kim; Youngjoo Choi; Huan H Nguyen; Man Ki Song; Jun Chang
Journal:  Immune Netw       Date:  2013-12-20       Impact factor: 6.303

8.  Sublingual Immunization with Chimeric C1q/CD40 Ligand/HIV Virus-like Particles Induces Strong Mucosal Immune Responses against HIV.

Authors:  Dongliang Liu; Sheng Zhang; Ethan Poteet; Christian Marin-Muller; Changyi Chen; Qizhi Yao
Journal:  Vaccines (Basel)       Date:  2021-10-23

Review 9.  Buccal and sublingual vaccine delivery.

Authors:  Heleen Kraan; Hilde Vrieling; Cecil Czerkinsky; Wim Jiskoot; Gideon Kersten; Jean-Pierre Amorij
Journal:  J Control Release       Date:  2014-06-06       Impact factor: 9.776

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.